Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sentinel Research, Communication Transparency Needed, GSK’s Troy Urges

Executive Summary

FDA needs a more open, transparent process for developing plans for drug safety studies in its Sentinel electronic data surveillance project as well as for announcing results, GlaxoSmithKline Senior VP and General Counsel Daniel Troy urged during a conference on Sentinel Jan. 12.
Advertisement

Related Content

Equal Access To Data Needed For CER To Be Effective, NPC Exec Says
Equal Access To Data Needed For CER To Be Effective, NPC Exec Says
PDUFA V: Sentinel, Regulatory Science Upgrades Could Gain User Fee Funding
PDUFA V: Sentinel, Regulatory Science Upgrades Could Gain User Fee Funding
Onglyza Data From Sentinel Pilot Can Be Validated By Phase IV Trial, FDA Says
Onglyza Data From Sentinel Pilot Can Be Validated By Phase IV Trial, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS053085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel